COGT logo

COGENT BIOSCIENCES INC

COGTNASDAQ
🏆 #1243 by market capUS Equity
$807.16▲ $7.67 (+0.95%)
Simulated price
🔔
Track COGT
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 0.9%
7d▲ 2373.7%
14d▲ 2365.4%
30d▲ 2227.5%
ytd▲ 2172.4%
1y▲ 5604.3%
🏦Market Cap
$5.53B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
238.7x
Expensive
Otter Score
48
Weak

Trading Snapshot

Day Range
$802.55 – $819.87
52-Week Range
$12.97 – $43.73
Volume
$2.74B
Avg Volume
$1.84B
Shares Outstanding
170.9M
Next Earnings
Dec 6, 2026

Fundamentals Snapshot

Annual Revenue
$23M
Last Q Revenue
$6M
P/E Ratio
—
P/S Ratio
238.7x
EPS (TTM)
$-2.44
Dividend Yield
—
Dilution (1yr)
+45.7%

Why Investors Own COGT

  • ✓High-growth profile — revenue up +19.8% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 51% gross margin and 8% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

COGT logo

COGENT BIOSCIENCES INC

COGT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$333M▲ +20.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$266M▲ +27.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
161.0M▲ +45.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$59M▼ −$22M YoY
StockOtter · stockotter.space

About COGENT BIOSCIENCES INC

Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
48/100

Analyst Price Target

ⓘ
Average Target
$883.74
▲ +9.5% Upside
High Target$1,108.68
Low Target$749.50
Based on 24 analysts

Latest News & Updates

🚀
Bloomberg·2h ago

COGENT BIOSCIENCES INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift COGT price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

COGENT BIOSCIENCES INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.